|
Abdominal Pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We present a case of HER2-related therapy-induced diarrhea and abdominal pain managed successfully with Rifaximin.
|
28848707 |
2017 |
|
Acinar Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
HER2 was overexpressed in 34 of 319 (10.65%) mucoepidermoid carcinomas, one of 170 (0.59%) acinic cell adenocarcinomas and three of 14 (21.43%) salivary duct carcinomas.
|
21670724 |
2011 |
|
Acinar Cell Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Acinic cell carcinoma (ACC) of the breast is a rare form of triple-negative (that is, oestrogen receptor-negative, progesterone receptor-negative, HER2-negative) salivary gland-type tumour displaying serous acinar differentiation.
|
26011570 |
2015 |
|
Acoustic Neuroma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Our findings support the role of ERBB2 in VS development and growth.
|
23179934 |
2013 |
|
Acoustic Neuroma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients.
|
29948766 |
2018 |
|
Acoustic Neuroma
|
0.070 |
AlteredExpression
|
disease |
LHGDN |
These findings implicate a functional role of ErbB-2 in the benign nature of VS and that a rationale for using ErbB targeted therapies in VS may be warranted.
|
17964790 |
2007 |
|
Acoustic Neuroma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Protein extracts from VS or rat sciatic nerve (proximal or distal to a crush injury) were isolated into lipid raft and nonraft fractions and immunoblotted for erbB2, phosphorylated erbB2, and merlin (for sciatic nerve).
|
18199961 |
2008 |
|
Acoustic Neuroma
|
0.070 |
Biomarker
|
disease |
BEFREE |
VS upregulated epidermal growth factor (EGF) receptor in 68% (62% sporadic and 75% NF2-associated VS) and ErbB2 in 84% (76% sporadic and 94% NF2-related VS).
|
18199957 |
2008 |
|
Acoustic Neuroma
|
0.070 |
Biomarker
|
disease |
BEFREE |
We have previously shown that VSs produce the glial growth factor, neuregulin-1 (NRG1), and its receptors, ErbB2 and ErbB3.
|
16432850 |
2006 |
|
Acoustic Neuroma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Our findings with immunohistochemistry and western blot analysis indicate a level of ErbB-1 similar to normal peripheral nerve, but a high expression of ErbB-2 similar to the vestibular schwannoma and glioblastoma multiforme.
|
20547458 |
2010 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutated EGFRs also hyperphosphorylate the related erythroblastic leukemia viral oncogene (ErbB) family member, ErbB-2, in a similar manner.
|
24019492 |
2013 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erythroblastic leukemia viral oncogene homolog 2 (C-erbB-2) and cyclooxygenase-2 (Cox-2) were examined using immunohistochemical and immunofluorescence assay, respectively.
|
29501042 |
2018 |
|
Acute Erythroblastic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAX2 (paired box 2) transcription factor is expressed by breast cancer cells in vivo and recently, it was shown to negatively regulate the expression of ERBB2 (erythroblastic leukemia viral oncogene homolog 2, HER-2/neu), a well-documented pro-invasive and pro-metastastic gene, in luminal/ERalpha-positive (ERα+) breast cancer cells.
|
22168360 |
2011 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a combination of anatomical, pharmacological, genetic, and behavioral approaches, the present study investigated the role of erbb2 (a homolog of the avian erythroblastic leukemia viral oncogene homolog 2) and the erbb2-interacting gene, erbin, in the sexual differentiation of the song nucleus HVC in the Bengalese finch.
|
29082632 |
2018 |
|
Acute Erythroblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This mutation reduced the expression of mature miR-125a and alleviated its inhibitory effect on erythroblastic leukemia viral oncogene homolog 2 (ERBB2) gene expression and on gastric tumor cell proliferation.
|
25109760 |
2014 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, we discovered that in the malignant pheochromocytomas, 6 of the 9 patients (67%) showed erythroblastic leukemia viral oncogene homolog 2 (ERBB-2) oncogene gain, whereas only 12 of the 34 (35%) identified change in the benign and extra-adrenal pheochromocytomas.
|
18310300 |
2008 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, have investigated whether or not the expression levels, of selected genes [tumor necrosis factor-α (TNFα), interleukin 6 (IL-6), adiponectin, leptin, C-reactive protein (CRP), parathyroid hormone (PTH), tumor protein 53 (TP53) and erythroblastic leukemia viral oncogene 2 (ErbB2)] were altered in blood samples of lean, overweight/obese and breast cancer subjects.
|
24961464 |
2014 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared the effect of these siRNAs on colony growth of the hormone receptor positive (MCF7) and Human Epidermal Growth Factor Receptor 2/c- Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2/c-erb-b2) positive (SK-BR-3) cells on the Test Cancer BioChip.
|
23049944 |
2012 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In both panels, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) was the most differentially expressed gene between the HER2 + and HER2 - tumors and seven additional genes had p-values < 0.05 and log2 -fold changes > ;0.5; in expression between HER2 + and HER2 - tumors: topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-fos fbj murine osteosarcoma viral oncogene homolog (FOS), wingless-type mmtv integration site family, member 5a (WNT5A), growth factor receptor-bound protein 7 (GRB7), cell division cycle 2 (CDC2), and baculoviral iap repeat-containing protein 5 (BIRC5).
|
21172013 |
2010 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
One of these responses is the endothelial release of NRG (neuregulin)-1-a paracrine growth factor activating ErbB2 (erythroblastic leukemia viral oncogene homolog B2), ErbB3, and ErbB4 receptor tyrosine kinases on various targets cells.
|
31607147 |
2019 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies in genetically modified mice have demonstrated that neuregulin-1 (NRG-1), along with the erythroblastic leukemia viral oncogene homolog (ErbB) 2, 3, and 4 receptor tyrosine kinases, is necessary for multiple aspects of cardiovascular development.
|
23104879 |
2012 |
|
Acute Erythroblastic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rare but targetable mutations such as avian erythroblastic leukemia viral oncogene homolog 2 (erb-b2 receptor tyrosine kinase 2) (<i>ERBB2</i>; human epidermal growth factor receptor 2 [<i>HER2</i>]) transmembrane domain (TMD) mutations can be detected by comprehensive genomic profiling.Afatinib may be effective for patients with cancer with <i>ERBB2</i> (<i>HER2</i>) TMD mutations.In order to implement precision oncology, it is important to establish a database of integrated information regarding the clinical genomes and therapeutic outcomes of patients with recurrent but less common mutations.
|
29146616 |
2018 |
|
Acute Erythroblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we showed that WWP1 upregulates and maintains erythroblastic leukemia viral oncogene homolog 2 (ErbB2) and epithelial growth factor receptor (EGFR) in multiple cell lines.
|
18724389 |
2008 |
|
Acute heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In summary, the ErbB signaling pathway and, especially, HER2/ErbB2 receptor expression are significantly associated with some of the recognized, clinically significant parameters of patients with acute heart failure.
|
23975515 |
2013 |
|
Acute lymphocytic leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Besides providing evidence that HER2/neu expression is no risk factor in ALL patients, our data demonstrates that HER2/neu can be a promising target for Trastuzumab therapy in the subset of ALL patients with the potential to improve disease outcome.
|
26887048 |
2016 |